RESONANCE HEALTH LIMITED

ASX

RHT

Resonance Health Limited is principally engaged in the development and commercialization of technologies and services for the quantitative analysis of radiological images. The Company's segments include Services, Research and Development, and Corporate. The Company's core product is FerriScan, which is a non-invasive liver diagnostic technology used for the measurement of iron in the liver. FerriScan is used for liver iron concentration (LIC) measurement from magnetic resonance imaging (MRI) scans of a patient's liver. The FerriScan analysis procedure produces a mean LIC measurement and a color coded map reflecting the iron distribution across the liver. The Company's product HepaFat-Scan, is a non-invasive method for measuring volumetric liver fat fraction (VLFF) from MRI scans. HepaFat-Scan is provided as an image analysis service. HepaFat-Scan is available for routine clinical use and for use in pharmaceutical company clinical trials.